Collaborative and Other Relationships (Tables)

12 Months Ended

Dec. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Co-promotion profit sharing formula

Our share of annual co-promotion profits in excess of $50.0 million varies, as summarized in the table below, upon the following events:

After First GAZYVA Threshold Date until Second GAZYVA Threshold Date	37.5	%
After Second GAZYVA Threshold Date	35.0	%

Pretax profit sharing formula

Our share of annual profits in excess of $50.0 million varies, as summarized in the table below, upon the following events:

After First GAZYVA Threshold Date until Second GAZYVA Threshold Date	37.5	%
After Second GAZYVA Threshold Date	35.0	%

Revenues from anti-CD20 therapeutic programs

Revenue from anti-CD20 therapeutic programs is summarized in the table below. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.

	For the Years Ended December 31,
(In millions)	2021		2020		2019
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA	$	647.7	$	1,080.2	$	1,542.4
Other revenue from anti-CD20 therapeutic programs	1,010.8		897.6		748.0
Total revenue from anti-CD20 therapeutic programs	$	1,658.5	$	1,977.8	$	2,290.4

Revenue from anti-CD20 therapeutic programs is summarized as follows:

	For the Years Ended December 31,
(In millions)	2021		2020		2019
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA	$	647.7	$	1,080.2	$	1,542.4
Other revenue from anti-CD20 therapeutic programs	1,010.8		897.6		748.0
Total revenue from anti-CD20 therapeutic programs	$	1,658.5	$	1,977.8	$	2,290.4

Summary of activity related to BAN2401 and Elenbecestat collaboration

A summary of development and sales and marketing expense related to the Lecanemab Collaboration is as follows:

	For the Years Ended December 31,
(In millions)	2021		2020		2019
Total development expense incurred by the collaboration related to the advancement of lecanemab and elenbecestat	$	323.0	$	219.3	$	348.7
Biogen's share of lecanemab and elenbecestat development expense reflected in research and development expense in our consolidated statements of income	161.5		109.6		174.3
Total sales and marketing expense incurred by the Lecanemab Collaboration	27.2		9.8		32.4
Biogen's share of lecanemab and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income	13.6		4.9		16.2

Summary of activity related to Aducanumab collaboration

A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:

	For the Years Ended December 31,
(In millions)	2021		2020		2019
Total ADUHELM development expense	$	183.7	$	152.0	$	179.4
Biogen's share of ADUHELM development expense reflected in research and development expense in our consolidated statements of income	101.1		83.6		98.7
Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement	562.3		353.0		27.4
Biogen's share of ADUHELM sales and marketing expense reflected in selling, general and administrative expense and collaboration profit (loss) sharing in our consolidated statements of income	301.4		193.7		15.1
Total ADUHELM collaboration third-party milestones	100.0		75.0		—
Biogen's share of reimbursement from Eisai of ADUHELM milestone payments reflected in collaboration profit (loss) sharing in our consolidated statements of income	45.0		33.8		—

Summary of activity related to the UCB collaboration

A summary of development expense related to the UCB collaboration agreement is as follows:

	For the Years Ended December 31,
(In millions)	2021		2020		2019
Total UCB collaboration development expense	$	84.2	$	58.3	$	31.9
Biogen's share of UCB development expense reflected in research and development expense in our consolidated statements of income	42.1		29.2		16.0

Summary of Activity Related to Sage Therapuetics

A summary of development and sales and marketing expense related to this collaboration is as follows:

	For the Years Ended December 31,
(In millions)	2021
Total Sage collaboration development expense	$	167.7
Biogen's share of Sage development expense reflected in research and development expense in our consolidated statements of income	83.8
Total Sage sales and marketing expense incurred by the collaboration	36.4
Biogen's share of Sage sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income	18.2

Summary of Activity Related to Denali Therapeutics Collaboration

A summary of development expense related to this collaboration is as follows:

	For the Years Ended December 31,
(In millions)	2021		2020		2019
Total Denali collaboration development expense	$	42.5	$	14.6	$	—
Biogen's share of Denali development expense reflected in research and development expense in our consolidated statements of income	25.5		8.8		—

Summary of Activity Related to Sangamo Therapeutics

A summary of development expense related to this collaboration is as follows:

	For the Years Ended December 31,
(In millions)	2021		2020		2019
Total Sangamo collaboration development expense	$	22.7	$	10.1	$	—
Biogen's share of Sangamo development expense reflected in research and development expense in our consolidated statements of income	14.6		6.4		—